Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer

Annals of Oncology

Volumn 24, Issue 7, 2013, Pages 1762-1769

  Van Dijk, T H ^a   Tamas, K ^a   Beukema, J C ^a   Beets, G L ^b   Gelderblom, A J ^c   de Jong, K P ^a   Nagtegaal, I D ^d   Rutten, H J ^e   van de Velde, C J ^c   Wiggers, T ^a   Hospers, G A ^a   Havenga, K ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CATHARINA HOSPITAL   (Netherlands)

Author keywords

Bevacizumab; Neoadjuvant chemotherapy; Preoperative radiotherapy; Rectal cancer; Stage IV

Indexed keywords

BEVACIZUMAB; CAPECITABINE; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION; LIVER METASTASIS; LUNG METASTASIS; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NETHERLANDS; OVERALL SURVIVAL; PAIN; PATIENT COMPLIANCE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROCTITIS; PROSPECTIVE STUDY; RECTUM CANCER; RECURRENCE RISK; SENSORY NEUROPATHY; SHORT COURSE THERAPY; SKIN DISEASE; VASCULAR DISEASE;

BEVACIZUMAB; NEOADJUVANT CHEMOTHERAPY; PREOPERATIVE RADIOTHERAPY; RECTAL CANCER; STAGE IV;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DOSE FRACTIONATION; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RECTUM; TREATMENT OUTCOME;

EID: 84883802248     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt124     Document Type: Article

References (46)

1. Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2009; 1: CD006041.
2. Gerard JP, Conroy T, Bonnetain F et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620-4625.
3. Czito BG, Bendell JC, Willett CG et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results. Int J Radiat Oncol Biol Phys 2007; 68: 472-478.
4. Czito BG, Willett CG. Beyond 5-fluorouracil: the emerging role of newer chemotherapeutics and targeted agents with radiation therapy. Semin Radiat Oncol 2011; 21: 203-211.
5. Willett CG, Duda DG, Czito BG et al. Targeted therapy in rectal cancer. Oncology (Williston Park) 2007; 21: 1055-1065.
6. Willett CG, Duda DG, di Tomaso E et al. Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol 2007; 4: 316-321.
7. Dipetrillo T, Pricolo V, Lagares-Garcia J et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys 2012; 82: 124-129.
8. Resch G, De Vries A, Öfner D et al. Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer-a two stage phase II clinical trial. Radiother Oncol 2012; 102: 10-13.
9. Helbling D, Bodoky G, Gautschi O et al. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Ann Oncol 2012; 3: 718-725.
10. Verhoef C, van der Pool AE, Nuyttens JJ et al. The 'liver-first approach' for patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum 2009; 52: 23-30.
11. Glimelius B, GrÖnberg H, Järhult J et al. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003; 42: 476-492.
12. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72: 15-24.
13. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
14. Quirke P, Durdey P, Dixon MF et al. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986; 2: 996-999.
15. Mandard AM, Dalibard F, Mandard JC et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-2686.
16. Nagtegaal ID, van de Velde CJ, van der Worp E et al. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol 2002; 20: 1729-1734.
17. Kele PG, de Jong KP, van der Jagt EJ. Increase in volume of ablation zones during follow-up is highly suggestive of ablation site recurrence in colorectal liver metastases treated with radiofrequency ablation. J Vasc Interv Radiol 2012; 23: 537-544.
18. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985; 69: 1375-1381.
19. Adam R, Avisar E, Ariche A et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8: 347-353.
20. Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311-1319.
21. Nordlinger B, Van Cutsem E, Rougier P et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007; 43: 2037-2045.
22. Okines A, Puerto OD, Cunningham D et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009; 101: 1033-1038.
23. Bosset JF, Calais G, Mineur L et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. J Clin Oncol 2005; 23: 5620-5627.
24. de Campos-Lobato LF, Stocchi L, da Luz Moreira A et al. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol 2011; 18: 1590-1598.
25. Garcia-Aguilar J, Smith DD, Avila K et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 2011; 254: 97-102.
26. Maas M, Nelemans PJ, Valentini V et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11: 835-844.
27. Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg 2012; 99: 918-928.
28. Yeo SG, Kim DY, Kim TH et al. Tumor volume reduction rate measured by magnetic resonance volumetry correlated with pathologic tumor response of preoperative chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2010; 78: 164-171.
29. de Bruin AF, Nuyttens JJ, Ferenschild FT et al. Preoperative chemoradiation with capecitabine in locally advanced rectal cancer. Neth J Med 2008; 66: 71-76.
30. Radu C, Berglund A, Påhlman L et al. Short-course preoperative radiotherapy with delayed surgery in rectal cancer-a retrospective study. Radiother Oncol 2008; 87: 343-349.
31. Graf W, Dahlberg M, Osman MM et al. Short-term preoperative radiotherapy results in down-staging of rectal cancer: a study of 1316 patients. Radiother Oncol 1997; 43: 133-137.
32. Hatfield P, Hingorani M, Radhakrishna G et al. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol 2009; 92: 210-214.
33. Pettersson D, Holm T, Iversen H et al. Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br J Surg 2012; 99: 577-583.
34. Wong SL, Mangu PB, Choti MA et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010; 28: 493-508.
35. Mulier S, Ni Y, Jamart J et al. Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? Ann Surg Oncol 2008; 15: 144-157.
36. Elias D, Baton O, Sideris L et al. Local recurrences after intraoperative radiofrequency ablation of liver metastases: a comparative study with anatomic and wedge resections. Ann Surg Oncol 2004; 11: 500-505.
37. Tol J, Koopman M, Rodenburg CJ et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008; 19: 734-738.
38. Willett CG, Duda DG, di Tomaso E et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27: 3020-3026.
39. Crane CH, Eng C, Feig BW et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2010; 76: 824-830.
40. Scappaticci FA, Fehrenbacher L, Cartwright T et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91: 173-180.
41. Mentha G, Majno PE, Andres A et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006; 93: 872-878.
42. Van der Pool AE, de Wilt JH, Lalmahomed ZS et al. Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases. Br J Surg 2010; 97: 383-390.
43. Butte JM, Gonen M, Ding P et al. Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. Cancer 2012; 1: 5414-5423.
44. Malik HZ, Gomez D, Wong V et al. Predictors of early disease recurrence following hepatic resection for colorectal cancer metastasis. Eur J Surg Oncol 2007; 33: 1003-1009.
45. Yamashita Y, Adachi E, Toh Y et al. Risk factors for early recurrence after curative hepatectomy for colorectal liver metastases. Surg Today 2011; 41: 526-532.
46. Folprecht G, Gruenberger T, Bechstein WO et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47.